Results 81 to 90 of about 69,003 (290)
CD68, CD80, CD86 and PD-L1 staining in liver biopsies.
, 2016 Biopsies from HBV-infected and control individuals were stained with mouse anti-human CD68 and rabbit anti-human CD80, CD86 or PD-L1 Abs. Representative photomicrographs showing (A) CD68 red staining indicating CD68+ cells and (B-D) CD80, CD86 or PD-L1 ...
Crystal Y. Koh (2605771) +9 more
core +1 more source
Advanced Science, EarlyView.To address the multifaceted imbalance in diabetic keratopathy, a light‐responsive biomimetic platform (WCNx‐Rh2) is developed and integrates glucose degradation, immune modulation, and antibacterial defense through a designed heterojunction and screened immunomodulator. WCNx‐Rh2 reduces AGEs/ROS and inflammatory signaling, reprogramming dendritic cells
Mengzhen Zhao +8 more
wiley +1 more source
CD80/CD28 co-stimulation in human brucellosis [PDF]
Clinical and Experimental Immunology, 2006 SummaryDespite treatment, 10–30% of brucellosis patients develop chronic disease, characterized by atypical clinical picture and/or relapses. A defective T helper 1 (Th1) response and a long percentage of CD4+/CD25+ cells have been described in chronic brucellosis patients.
P, Skendros +3 more
openaire +2 more sources
Advanced Science, EarlyView.A NIR‐II light‐activatable thermoelectric nanoreactor converts surface‐bound Cu2+ into bioactive Cu+ via directed electron flow. This spatiotemporally controlled reduction triggers potent cuproptosis and immunogenic cell death, eradicating primary tumors and, together with aPD‐1 therapy, suppressing metastases while establishing durable immune memory ...
Boyu Yuan +10 more
wiley +1 more source
CD80 Expressed by CD8+ T Cells Contributes to PD-L1-Induced Apoptosis of Activated CD8+ T Cells
Journal of Immunology Research, 2017 Tumor cells are capable of limiting antitumor CD8+ T cell responses through their cell surface expression of PD-L1. In addition to PD-1 expressed by CD8+ T cells, PD-L1 also binds to CD80 expressed by CD8+ T cells.
Meagan R. Rollins +1 more
doaj +1 more source
CD40-mediated CD80 upregulation is defective in HOIP-deficient cells.
, 2013 Cells were incubated for 72 hrs with an isotype control antibody (left) or anti-CD40 antibody (right) and then stained for expression of CD80 (filled profiles indicate staining with anti-CD80 antibody; open profiles are staining with an isotype control ...
John D. Colgan (346935) +3 more
core +1 more source
Autoantigen mRNA‐LNP Vaccination Drives Therapeutic Efficacy in Preclinical Models for Autoimmunity
Advanced Science, EarlyView.Systemic and intramuscular delivery of autoantigen mRNA via lipid nanoparticles reprograms antigen‐presenting cells toward a mature, homeostatic state, driving antigen‐specific T cell exhaustion and providing therapeutic efficacy across autoimmune disease models.
Paulien Baeten +30 more
wiley +1 more source
Context-restricted PD-(L)1 checkpoint agonism by CTLA4-Ig therapies inhibits T cell activity
Cell ReportsSummary: T cell surface CTLA4 sequesters the costimulatory ligands CD80 and CD86 on antigen-presenting cells (APCs) to prevent autoimmunity. Therapeutic immunosuppression by recombinant CTLA4-immunoglobulin (Ig) fusion proteins, including abatacept, is ...
Ethan P. Oxley +22 more
doaj +1 more source
PMN membranes disassociate IRAK-M from CD80.
, 2013 Macrophages were treated with PMN lipid rafts for various times Panel A. Co-IP demonstrates CD80 binds IRAK-M in resting PMA differentiated THP-1 macrophages, lane 1. One hour after lipid raft treatment IRAK-M disassociates from CD80, lane 2.
Hiroshi Kobayashi (23858) +9 more
core +1 more source
Advanced Science, EarlyView.Schematic illustration of a biomimetic SKEV@AAV platform targeting p21‐high senescent Kupffer cells (sKCs) in hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT). p21‐high sKCs accumulate in the PVTT microenvironment and establish an immunosuppressive, SASP‐rich environment that facilitates tumor cell proliferation and immune evasion.
Na Ta +10 more
wiley +1 more source